✦ LIBER ✦

Pamidronate associated with high incremental costs per adverse event avoided in patients with metastatic breast cancer

✍ Scribed by Martine Extermann

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost analysis of secondary prophylaxis w

✍ Dorothy Romanus; Neill Iscoe; Carlo DeAngelis; Neil Shear; Thomas R. Einarson 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 189 KB

Adverse Events Associated With Bevacizum

✍ Shankaran, Veena; Mummy, David; Koepl, Lisel; Blough, David; Yim, Yeun Mi; Yu, E 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 150 KB

PCN51 Comprehensive Investigation of Adv

✍ S.A. Hurvitz; A. Guerin; M. Brammer; E. Guardino; Z.Y. Zhou; M.S. Kaminsky; E.Q. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Cost utility analysis of prophylactic pa

✍ G. Dranitsaris; Tom Hsu 📂 Article 📅 1999 🏛 Springer-Verlag 🌐 English ⚖ 73 KB

1241 POSTER Treatment costs of skeletal-

✍ J. Felix; V. Andreozzi; M. Soares; J. Passos-Coelho 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Cost of Adverse Events During Treatment

✍ Campone, M.; Yang, H.; Faust, E.; Kageleiry, A.; Signorovitch, J.; Zhang, J.; Ga 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB